The food allergy medicine spinout from UChicago has been backed by the institution itself in a $3.5m seed round.

ClostraBio, a US-based developer of food allergy medicines spun out from University of Chicago (UChicago), raised $3.5m yesterday in a seed round that featured the university.

Individual investor Joe Mansueto and two unnamed family investors, whose children have food allergies, also provided capital.

Founded in 2016, ClostraBio is developing a pill-based therapy to restore a strain of gut bacteria called Clostridia that is thought to stop allergens entering the bloodstream. The approach was tested on mice during an early set…